Trial Profile
Observational Serial Chart Review of Repatha Use in European Subjects With Hyperlipidaemia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Feb 2023
Price :
$35
*
At a glance
- Drugs Evolocumab (Primary)
- Indications Hyperlipidaemia; Hyperlipoproteinaemia type IIa
- Focus Therapeutic Use
- Acronyms HEYMANS
- Sponsors Amgen
- 01 Feb 2023 The study was originally designed to have up to 12 months of follow up, However following a protocol amendment in February 2018, the follow up period was extended to 30 months.
- 01 Feb 2023 Final Results(n=1951) assessing evolocumab persistence and discontinuation over 30 months of evolocumab treatment and to evaluate at a population level the variability in LDL-C level reductions during the study period published in the Atherosclerosis
- 29 Aug 2022 Results of analyses assessing metrics of variability at population level in LDL-C reduction over time with evolocumab treatment presented at the ESC Congress 2022 - Annual Congress of the European Society of Cardiology